Keywords: gilead, letairis, gets, fda, ok, who, class
Gilead's Letairis gets FDA OK for WHO Class I/II pulmonary arterial hypertension
Article | 25 June 2007
The US Food and Drug Aministration's approval of Letairis (ambrisentan) as a once-daily treatment for pulmonary arterial hypertension is, according ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
